News
| 7 min read
They’re approved by the FDA and Medicare and inching closer to widespread adoption nationally. But how good are they at detecting colorectal cancer?
| 5 min read
From virtual control groups to brain organoids, new approach methodologies are transforming how drugs and cosmetics are tested for safety.
| 3 min read
Automation may help address longstanding bottlenecks in CAR-T and TCR-T development
| 5 min read
Early clinical data suggest that intratumoral delivery may halt tumor activity and support bone regeneration in metastatic breast cancer.
| 6 min read
A clinical trial showed that Rhapsido can safely and effectively treat chronic spontaneous urticaria; its developer Novartis hopes that’s just the start.
| 5 min read
Emerging optogenetic, gene, and cell therapies are moving beyond single-gene treatments, offering hope for a broader range of patients with retinitis pigmentosa.
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
| 4 min read
FDA updates, pharma tariff agreements, gene editing deals, and more led the news this week.
| 3 min read
QDX and Prelude Therapeutics are developing drugs that selectively target the JAK2 V617F mutation, offering hope for patients with myeloproliferative neoplasms.
| 7 min read
While amyloid plaques form first, new work suggests targeting tau tangles that spread through the brain could also help the fight against this devastating disease.
| 10+ min read
Bioelectricity is a potent lever for controlling health. What would it look like to treat the body electrically, rather than chemically?
| 3 min read
Scientists created a novel platform that uses the advantages of both bacteria and viruses to attack tumors.
